ACAD ACADIA Pharmaceuticals Inc. - Common Stock
$29,17
Kurs · Aug 18, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$20–$30
93% of range
Analystenbewertung
BUY
27 analysts
Kursziel
$34
+16% upside
P/E (TTM)
12.7
ROE
38.1%
Nettogewinnmarge
36.5%
Über ACADIA Pharmaceuticals Inc. - Common Stock Unternehmensübersicht von Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Mehr lesen
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
ACAD Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$29.17
Marktkapitalisierung
$4.97B
P/E (TTM)
12.7
EPS (TTM)
$2.30
Umsatz (TTM)
$1.07B
Dividendenrendite
—
ROE
38.1%
Verschuldungsgrad
—
52W-Spanne
$20 – $30
ACAD Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$1.07B
2016-12-31
→
2025-12-31
EPS
$2.30
2020-12-31
→
2025-12-31
Freier Cashflow
$105M
2016-12-31
→
2025-12-31
Margen
36.5%
2016-12-31
→
2023-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
ACAD
Peer-Median
P/E (TTM)
12.7
13.2
P/S (TTM) (K/V (TTM))
4.6
55.3
P/B (K/B)
4.0
3.5
Price / FCF (Kurs / FCF)
47.2
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
ACAD
Peer-Median
Operating Margin (Betriebsgewinnmarge)
9.8%
—
Net Profit Margin (Nettogewinnmarge)
36.5%
-151.2%
ROA
28.4%
-42.2%
ROE
38.1%
-52.8%
ROIC
24.0%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
ACAD
Peer-Median
Current Ratio (Liquiditätsgrad)
3.8
10.3
Quick Ratio
1.1
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
ACAD
Peer-Median
Revenue YoY (Umsatz YoY)
11.9%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
27.5%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
19.4%
—
EPS YoY (EPS VjV)
69.1%
—
Net Income YoY (Nettogewinn YoY)
72.7%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
ACAD
Peer-Median
ACAD Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
27 Analysten
- Starker Kauf 7 25,9%
- Kauf 14 51,9%
- Halten 5 18,5%
- Verkauf 1 3,7%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
20 Analysten · 2026-08-18
Median
$36.00
Jetzt
$29.17
Tief
$17.00
Hoch
$49.00
Median-Ziel
$36.00
+23,4%
Mittelwert-Ziel
$33.85
+16,0%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.30%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $0.18 | $0.06 | 0.12% |
| 31. März 2026 | $0.02 | $0.06 | -0.04% |
| 31. Dezember 2025 | $1.60 | $0.14 | 1.5% |
| 30. September 2025 | $0.42 | $0.15 | 0.27% |
| 30. Juni 2025 | $0.16 | $0.14 | 0.02% |
| 31. März 2025 | $0.11 | $0.11 | -0.00% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | — |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | — |
| CAI | $7.62B | -8.4 | 97.0% | -8.4% | -13.2% | — |
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | — |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | — |
| DYN | $3.23B | -5.6 | — | — | -57.8% | — |
| CELC | $4.81B | -26.3 | — | — | -244.3% | — |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | — |
| PBLS | — | — | — | — | — | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Bilanz 25
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Cashflow 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Rentabilität 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Wachstumsraten 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | -335,115,000 | 168,836,000 | 167,827,000 | 166,808,000 | -330,606,000 | 165,974,000 | 165,551,000 | 164,798,000 | -326,136,000 | 164,234,000 | 163,458,000 | 162,263,000 | 128,494 | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | -337,080,000 | 170,650,000 | 168,681,000 | 167,668,000 | -332,613,000 | 166,178,000 | 166,174,000 | 166,623,000 | -327,724,000 | 164,234,000 | 165,046,000 | 162,263,000 | 128,494 | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.12B | $1.06B | · | $1.04B | $1.00B | $943M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $134M | $121M | · | $150M | $112M | $102M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 32.4 | 31.4 | · | 24.0 | 32.2 | 27.2 | · | 19.7 | 90.3 | -1849.0 | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.9 | 3.6 | · | 3.5 | 3.6 | 2.9 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| P / FCF | · | 132.4 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.1% | 3.2% | · | 4.2% | 3.1% | 3.7% | · | 5.1% | 1.1% | -0.05% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $1.07B | $958M | $726M | $517M | $484M |
| Bruttogewinnmarge % | — | — | 94.3% | 98.0% | 97.8% |
| Betriebsgewinnmarge % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Nettoergebnis | $391M | $226M | $-61M | $-216M | $-168M |
| Verwässerte EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $105M | $157M | $17M | $-114M | $-127M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 387 Einreicher · $3.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 56 (+10 vs. Vorquartal) | 37 (+10 vs. Vorquartal) | 136 (+11 vs. Vorquartal) | 100 (-13 vs. Vorquartal) | +17.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1.085.696.471 | 42.912.904 | 33,44% | Aktien |
| STATE STREET CORP | $229.628.164 | 9.076.212 | 7,07% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223.612.785 | 8.838.450 | 6,89% | Aktien |
| RTW INVESTMENTS, LP | $180.756.457 | 7.144.524 | 5,57% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $145.822.875 | 5.763.750 | 4,49% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $88.971.384 | 3.516.656 | 2,74% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $73.088.127 | 2.888.204 | 2,25% | Aktien |
| Qube Research & Technologies Ltd | $61.899.233 | 2.446.610 | 1,91% | Aktien |
| Point72 Asset Management, L.P. | $61.559.150 | 2.433.168 | 1,90% | Aktien |
| CITADEL ADVISORS LLC | $53.414.195 | 2.111.233 | 1,65% | Aktien |
| Pictet Asset Management Holding SA | $50.146.450 | 1.983.198 | 1,54% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49.826.959 | 1.969.445 | 1,53% | Aktien |
| MARSHALL WACE, LLP | $44.649.289 | 1.764.794 | 1,38% | Aktien |
| BRAIDWELL LP | $41.653.895 | 1.646.399 | 1,28% | Aktien |
| NORGES BANK | $41.069.692 | 1.623.308 | 1,26% | Aktien |
| Frazier Life Sciences Management, L.P. | $36.386.409 | 1.438.198 | 1,12% | Aktien |
| Artisan Partners Limited Partnership | $33.525.890 | 1.325.134 | 1,03% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $32.449.679 | 1.282.596 | 1,00% | Aktien |
| GOLDMAN SACHS GROUP INC | $32.070.584 | 1.267.612 | 0,99% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30.520.301 | 1.206.336 | 0,94% | Aktien |
| D. E. Shaw & Co., Inc. | $28.330.257 | 1.119.773 | 0,87% | Aktien |
| Allspring Global Investments Holdings, LLC | $26.143.513 | 1.037.441 | 0,81% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $23.452.898 | 926.992 | 0,72% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $23.082.961 | 912.370 | 0,71% | Aktien |
| BANK OF AMERICA CORP /DE/ | $21.702.062 | 857.789 | 0,67% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $17.985.922 | 710.906 | 0,55% | Aktien |
| Fisher Asset Management, LLC | $17.690.535 | 699.230 | 0,54% | Aktien |
| Allianz Asset Management GmbH | $15.730.341 | 706.664 | 0,48% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $15.657.841 | 618.887 | 0,48% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $14.925.077 | 589.924 | 0,46% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14.771.456 | 583.852 | 0,45% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.903.000 | 510.000 | 0,40% | Aktien |
| Hudson Bay Capital Management LP | $11.764.500 | 465.000 | 0,36% | Aktien |
| GLENMEDE TRUST CO NA | $11.656.544 | 460.733 | 0,36% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $11.599.190 | 458.466 | 0,36% | Aktien |
| Public Sector Pension Investment Board | $11.014.988 | 435.375 | 0,34% | Aktien |
| MACKENZIE FINANCIAL CORP | $10.646.872 | 420.825 | 0,33% | Aktien |
| Ishara Investments LP | $10.373.000 | 410.000 | 0,32% | Aktien |
| TWO SIGMA ADVISERS, LP | $9.888.042 | 370.200 | 0,30% | Aktien |
| Balyasny Asset Management L.P. | $9.817.007 | 388.024 | 0,30% | Aktien |
| BlackRock, Inc. | $9.281.482 | 366.857 | 0,29% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $9.020.310 | 356.534 | 0,28% | Aktien |
| AMERIPRISE FINANCIAL INC | $8.039.177 | 317.754 | 0,25% | Aktien |
| PRUDENTIAL FINANCIAL INC | $7.985.313 | 315.625 | 0,25% | Aktien |
| Alyeska Investment Group, L.P. | $7.850.261 | 310.287 | 0,24% | Aktien |
| RHUMBLINE ADVISERS | $7.663.389 | 302.902 | 0,24% | Aktien |
| Schonfeld Strategic Advisors LLC | $7.189.171 | 284.157 | 0,22% | Aktien |
| Edgestream Partners, L.P. | $7.167.515 | 283.301 | 0,22% | Aktien |
| Logos Global Management LP | $6.325.000 | 250.000 | 0,19% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $6.263.496 | 247.569 | 0,19% | Aktien |
| FMR LLC | $6.052.317 | 239.222 | 0,19% | Aktien |
| Swiss National Bank | $5.841.871 | 230.904 | 0,18% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $5.432.213 | 214.712 | 0,17% | Aktien |
| ALPS ADVISORS INC | $4.985.340 | 197.049 | 0,15% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $4.926.239 | 194.713 | 0,15% | Aktien |
| Legal & General Group Plc | $4.918.245 | 194.397 | 0,15% | Aktien |
| FIRST TRUST ADVISORS LP | $4.664.965 | 184.386 | 0,14% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $4.364.807 | 172.522 | 0,13% | Aktien |
| Birchview Capital, LP | $4.326.300 | 171.000 | 0,13% | Aktien |
| MARTINGALE ASSET MANAGEMENT L P | $4.247.693 | 167.893 | 0,13% | Aktien |
| Tetragon Partners GP Ltd | $4.247.238 | 167.875 | 0,13% | Aktien |
| GREAT LAKES ADVISORS, LLC | $3.822.526 | 151.088 | 0,12% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $3.635.306 | 143.688 | 0,11% | Aktien |
| STEMPOINT CAPITAL LP | $3.622.125 | 143.167 | 0,11% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $3.585.329 | 161.066 | 0,11% | Aktien |
| Squarepoint Ops LLC | $3.542.329 | 140.013 | 0,11% | Aktien |
| ORBIMED ADVISORS LLC | $3.466.100 | 137.000 | 0,11% | Aktien |
| Erste Asset Management GmbH | $3.369.240 | 133.700 | 0,10% | Aktien |
| Emerald Investment Advisers, LLC | $3.333.326 | 131.752 | 0,10% | Aktien |
| Caption Management, LLC | $3.289.000 | 130.000 | 0,10% | Verkaufsoption |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.130.217 | 123.724 | 0,10% | Aktien |
| WELLS FARGO & COMPANY/MN | $3.084.475 | 121.916 | 0,09% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.077.311 | 138.244 | 0,09% | Aktien |
| Longaeva Partners L.P. | $2.968.145 | 117.318 | 0,09% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2.948.791 | 116.553 | 0,09% | Aktien |
| Trexquant Investment LP | $2.935.357 | 116.022 | 0,09% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2.909.778 | 115.011 | 0,09% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $2.868.477 | 113.289 | 0,09% | Aktien |
| Rafferty Asset Management, LLC | $2.789.426 | 110.254 | 0,09% | Aktien |
| Nan Fung Group Holdings Ltd | $2.605.495 | 102.984 | 0,08% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $2.406.232 | 95.108 | 0,07% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $2.344.000 | 92.648 | 0,07% | Aktien |
| ROYCE & ASSOCIATES LP | $2.324.691 | 91.885 | 0,07% | Aktien |
| HOHIMER WEALTH MANAGEMENT, LLC | $2.322.540 | 91.800 | 0,07% | Aktien |
| Point72 Europe (London) LLP | $2.305.047 | 108.015 | 0,07% | Aktien |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $2.134.076 | 79.898 | 0,07% | Aktien |
| Campbell & CO Investment Adviser LLC | $2.108.527 | 83.341 | 0,06% | Aktien |
| Verdad Advisers, LP | $2.090.514 | 82.629 | 0,06% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $2.072.576 | 81.920 | 0,06% | Aktien |
| CITADEL ADVISORS LLC | $2.049.300 | 81.000 | 0,06% | Kaufoption |
| GUGGENHEIM CAPITAL LLC | $1.979.776 | 78.252 | 0,06% | Aktien |
| WESBANCO BANK INC | $1.978.460 | 78.200 | 0,06% | Aktien |
| Phocas Financial Corp. | $1.954.299 | 77.245 | 0,06% | Aktien |
| MetLife Investment Management, LLC | $1.899.043 | 75.061 | 0,06% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.850.493 | 73.142 | 0,06% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.788.331 | 70.685 | 0,06% | Aktien |
| Freestone Grove Partners LP | $1.755.643 | 69.393 | 0,05% | Aktien |
| CenterBook Partners LP | $1.743.878 | 68.928 | 0,05% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $1.722.930 | 68.100 | 0,05% | Aktien |
| Illinois Municipal Retirement Fund | $1.693.380 | 66.932 | 0,05% | Aktien |
Unternehmensinsider 37 Insider · 19 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Stephen Davis | CEO | 6. Januar 2024 M | 96.521 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 25. März 2011 A | 69.916 | 0 | 0 | $0 |
| Elena Ridloff | EVP and CFO | 29. April 2021 M | 10.553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15. Oktober 2018 A | — | 0 | 0 | $0 |
| Thomas H Aasen | Exec. VP, CFO & CBO | 25. März 2011 A | 13.899 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21. November 2022 M | 61.234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16. Juni 2006 S | 317.756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, Head of Commercial | 6. Januar 2024 M | 30.949 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29. Juli 2026 M | 18.994 | 0 | 2 | $-432.662 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26. Juni 2026 S | 13.088 | 0 | 2 | $-412.253 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6. Januar 2024 M | 46.901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10. Februar 2023 A | — | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6. Januar 2021 M | 8.059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15. Oktober 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | VP, GC & Sec. | 25. März 2011 A | — | 0 | 0 | $0 |
| Roger Mills | Executive VP, Development | 25. März 2011 A | — | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8. Juli 2009 M | 20.000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7. März 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11. März 2005 A | — | 0 | 0 | $0 |
| Adora Ndu | Direktor | 29. Mai 2026 A | 32.908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Direktor | 29. Mai 2026 A | 33.489 | 0 | 0 | $0 |
| Jonathan Poole | Direktor | 29. Mai 2026 A | 2.010 | 0 | 0 | $0 |
| James M Daly | Direktor | 29. Mai 2026 A | 12.148 | 0 | 0 | $0 |
| Laura Brege | Direktor | 29. Mai 2026 A | 23.202 | 0 | 0 | $0 |
| Edmund Harrigan | Direktor | 29. Mai 2026 A | 43.148 | 0 | 0 | $0 |
| Daniel B Soland | Direktor | 1. Juni 2023 A | 28.002 | 0 | 0 | $0 |
| Torsten Rasmussen | Direktor | 11. Juni 2010 A | 4.000 | 0 | 0 | $0 |
| Leslie L Iversen | Direktor | 11. Juni 2010 A | 9.000 | 0 | 0 | $0 |
| Mary Ann Gray | Direktor | 11. Juni 2010 A | — | 0 | 0 | $0 |
| Michael T Borer | Direktor | 11. Juni 2010 A | — | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Direktor | 11. Juni 2010 A | 4.000 | 0 | 0 | $0 |
| Gordon M Binder | Direktor | 12. Juni 2009 A | 14.364 | 0 | 0 | $0 |
| Alan G Walton | Direktor | 12. Juni 2009 A | 25.979 | 0 | 0 | $0 |
| Martien Van Osch | Direktor | 10. Juni 2005 A | 1.168.892 | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 20. April 2005 A | 774.006 | 0 | 0 | $0 |
| Mark C. Schneyer | — | 6. August 2026 M | 67.828 | 0 | 3 | $-587.248 |
| John Joseph Kaiser | — | 20. Oktober 2008 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 6 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 Einreichungen | 26. Februar 2026 | 25,40% | Änderung | — | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 Einreichungen | 6. Juni 2013 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 2. Mai 2005 | — | Erste Einreichung | — | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29. April 2005 | — | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 77 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,89% | 13.265 SH | 8. August 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 3,29% | 407.914 SH | 8. August 2026 | Täglich |
| SBIO · ALPS ETF Trust | 2,35% | 175.740 NS | 31. Mai 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,87% | 109.972 SH | 8. August 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,32% | 34.855 NS | 30. April 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,25% | 59.514 SH | 8. August 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,85% | 195.542 NS | 30. April 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,56% | 13.607 NS | 30. April 2026 | N-PORT |
| IJT · iShares Trust | 0,40% | 1.176.933 SH | 8. August 2026 | Täglich |
| OASC · Unified Series Trust | 0,39% | 15.269 NS | 31. Mai 2026 | N-PORT |
| IBB · iShares Trust | 0,37% | 1.239.145 SH | 8. August 2026 | Täglich |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150.827 SH | 8. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,34% | 9.317 SH | 8. August 2026 | Täglich |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 61.606 NS | 30. April 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,24% | 24.003 NS | 31. Mai 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,23% | 20.369 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,23% | 1.166.817 SH | 8. August 2026 | Täglich |
| XJR · iShares Trust | 0,23% | 14.974 SH | 8. August 2026 | Täglich |
| GSSC · Goldman Sachs ETF Trust | 0,20% | 89.945 NS | 31. Mai 2026 | N-PORT |
| IJR · iShares Trust | 0,20% | 7.728.433 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137.860 SH | 8. August 2026 | Täglich |
| BIB · ProShares Trust | 0,19% | 6.303 NS | 31. Mai 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443.221 SH | 8. August 2026 | Täglich |
| BKSE · BNY Mellon ETF Trust | 0,17% | 6.035 NS | 30. April 2026 | N-PORT |
| SMMV · iShares Trust | 0,17% | 17.063 SH | 8. August 2026 | Täglich |
| SMLF · iShares Trust | 0,15% | 219.745 SH | 8. August 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47.683 NS | 30. April 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,14% | 137.072 SH | 8. August 2026 | Täglich |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,14% | 81.552 NS | 30. April 2026 | N-PORT |
| SAA · ProShares Trust | 0,12% | 1.498 NS | 31. Mai 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3.281.125 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,11% | 39.884 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741.237 SH | 8. August 2026 | Täglich |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,09% | 66.331 SH | 8. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.699.377 SH | 8. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,09% | 115.210 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,08% | 526.641 NS | 30. April 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 16.957 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,07% | 5.921 NS | 31. Mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,06% | 599.784 NS | 31. Mai 2026 | N-PORT |
| ISCB · iShares Trust | 0,06% | 5.636 SH | 8. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54.956 NS | 30. April 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7.411 SH | 8. August 2026 | Täglich |
| SMDX · Tidal Trust III | 0,04% | 2.306 NS | 30. April 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 4.033 SH | 8. August 2026 | Täglich |
| UWM · ProShares Trust | 0,04% | 4.631 NS | 31. Mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.457.036 SH | 8. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2.944.095 SH | 8. August 2026 | Täglich |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 14.209 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,04% | 346.329 SH | 8. August 2026 | Täglich |